Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Headwaters Capital. This analysis is provided for institutional research purposes only and is not investment advice.
"Headwaters underperformed in Q3 due to healthcare exposure amid GLP-1 drug fears, but the manager views concerns as overblown. Small cap valuations have reached historically attractive levels below previous troughs when bond yields were similar."
Headwaters Capital declined 7.8% net in Q3 2023 versus the Russell Mid Cap's 4.7% decline, bringing YTD performance to +13.5% net versus +3.9% for the benchmark. Two themes dominated Q3 performance: rising bond yields that pressured all asset classes, and fears around GLP-1 weight loss drugs impacting healthcare stocks. The portfolio's healthcare exposure, particularly Inspire Medical and UFP Technologies, drove underperformance as investors worried about reduced obesity levels affecting medical procedures. However, the manager believes these fears are overblown and that companies like Inspire could actually benefit as patients reduce BMI into treatable ranges. Qualys was the top contributor, benefiting from continued cybersecurity spending priorities despite broad IT budget pressure. The manager maintains an optimistic small cap outlook, noting current valuations are below historical trough levels seen when bond yields were similar to today's rates. The portfolio added to existing positions during the quarter while selling Cryoport due to slower cell therapy commercialization concerns. Headwaters continues opposing Danaher's $24 Abcam acquisition bid, believing fair value is $35-37 per share.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The manager demonstrates high conviction through specific position sizing language, detailed fundamental analysis of individual holdings, and strong opposition to the Abcam acquisition with specific price targets. The letter includes substantial company-specific commentary and clear investment theses for major positions.
Growth Outlook
The manager expresses optimism about small cap opportunities and believes current valuations are attractive, but acknowledges significant headwinds from rising bond yields and market fears around GLP-1 drugs affecting healthcare stocks.
Risk Appetite
The portfolio added to multiple existing positions during the quarter's weakness, showing willingness to deploy capital, but also sold a position (Cryoport) due to concerns, indicating selective risk-taking rather than aggressive deployment.
Capital Deployment
The portfolio added to multiple existing positions during the quarter's weakness, indicating moderate deployment activity. However, one position was sold and no new positions were added, suggesting selective rather than aggressive capital deployment.
Forward Guidance
The manager encourages investors to take advantage of recent weakness and maintains an optimistic outlook for small caps, but the guidance is measured rather than aggressively bullish given current market conditions.
Language Signal
Language includes positive terms like 'optimistic outlook' and 'attractive valuations' but is balanced with significant discussion of risks, fears, and market pressures. The tone is cautiously constructive rather than bullish.
Perceived Risk
The manager identifies multiple significant risks including rising bond yields pressuring valuations across asset classes, GLP-1 drug fears impacting healthcare stocks, and broad IT budget pressure. These risks are discussed in detail with specific market impacts quantified.
Opportunity Density
The manager sees attractive opportunities in small caps due to historically low valuations and believes the market has overshot appropriate levels. The letter emphasizes taking advantage of recent weakness, suggesting a relatively rich opportunity set despite near-term headwinds.
Time Horizon
The manager takes a multi-year view on investments, noting that GLP-1 drug impacts are 'likely years away' and focusing on long-term value creation. The Abcam analysis includes detailed forward-looking financial projections, indicating a medium to long-term investment horizon.
